No retraction, correction or concern found when last checked on Oct 24, 2026.

Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans

Alberto Cagigi, Karin Loré

Vaccines · 2021 · Review · CC BY

Abstract

In this concise review, we summarize the concepts behind mRNA vaccination. We discuss the innate and adaptive immune response generated by mRNA vaccines in different animal models and in humans. We give examples of viral infections where mRNA vaccines have shown to induce potent responses and we discuss in more detail the recent SARS-CoV-2 mRNA vaccine trials in humans.

References 84

1.
Wolff J., Malone R., Williams P., Chong W., Acsadi G., Jani A., Felgner P. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465-1468.
Not in our library10.1126/science.1690918
2.
Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259:1745-1749.
Not in our library10.1126/science.8456302
3.
Zhou X., Berglund P., Rhodes G., Parker S.E., Jondal M., Liljestrom P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine. 1994;12:1510-1514.
Not in our library10.1016/0264-410x(94)90074-4
4.
Martinon F., Krishnan S., Lenzen G., Magne R., Gomard E., Guillet J.G., Levy J.P., Meulien P. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 1993;23:1719-1722.
Not in our library10.1002/eji.1830230749
5.
Kariko K., Muramatsu H., Welsh F.A., Ludwig J., Kato H., Akira S., Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 2008;16:1833-1840.
Not in our library10.1038/mt.2008.200
6.
Schlake T., Thess A., Fotin-Mleczek M., Kallen K.J. Developing mRNA-vaccine technologies. RNA Biol. 2012;9:1319-1330.
Not in our library10.4161/rna.22269
7.
Graham B.S., Mascola J.R., Fauci A.S. Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases. JAMA. 2018;319:1431-1432.
Not in our library10.1001/jama.2018.0345
8.
Liang F., Lindgren G., Lin A., Thompson E.A., Ols S., Rohss J., John S., Hassett K., Yuzhakov O., Bahl K., et al. Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Mol. Ther. 2017;25:2635-2647.
Not in our library10.1016/j.ymthe.2017.08.006
9.
Hassett K.J., Benenato K.E., Jacquinet E., Lee A., Woods A., Yuzhakov O., Himansu S., Deterling J., Geilich B.M., Ketova T., et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol. Ther. Nucleic. Acids. 2019;15:1-11.
Not in our library10.1016/j.omtn.2019.01.013
10.
Kulkarni J.A., Cullis P.R., van der Meel R. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility. Nucleic. Acid. Ther. 2018;28:146-157.
Not in our library10.1089/nat.2018.0721
11.
Sands H., Gorey-Feret L.J., Cocuzza A.J., Hobbs F.W., Chidester D., Trainor G.L. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 1994;45:932-943.
Not in our library
12.
Reichmuth A.M., Oberli M.A., Jaklenec A., Langer R., Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 2016;7:319-334.
Not in our library10.4155/tde-2016-0006
13.
Chen S., Tam Y.Y.C., Lin P.J.C., Sung M.M.H., Tam Y.K., Cullis P.R. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J. Control. Release. 2016;235:236-244.
Not in our library10.1016/j.jconrel.2016.05.059
14.
Eygeris Y., Patel S., Jozic A., Sahay G. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery. Nano Lett. 2020;20:4543-4549.
Not in our library10.1021/acs.nanolett.0c01386
15.
Lee S., Cheng Q., Yu X., Liu S., Johnson L., Siegwart D.J. A Systematic Study of Unsaturation in Lipid Nanoparticles Leads to Improved mRNA Transfection In Vivo. Angew Chem. Int. Ed. Engl. 2020.
Not in our library10.1002/anie.202013927
16.
Persano S., Guevara M.L., Li Z., Mai J., Ferrari M., Pompa P.P., Shen H. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017;125:81-89.
Not in our library10.1016/j.biomaterials.2017.02.019
17.
Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 2007;357:1903-1915.
Not in our library10.1056/nejmoa066092
18.
Monath T.P., Gershman M., Erin Staples J., Barrett A.D.T., Plotkin S.A., Orenstein W.A., Offit P.A. Yellow fever vaccine. Vaccines. 2013;870-968.
Not in our library10.1016/b978-1-4557-0090-5.00043-4
19.
Medical Advisory Committee of the Immune Deficiency Foundation, Shearer W.T., Fleisher T.A., Buckley R.H., Ballas Z., Ballow M., Blaese R.M., Bonilla F.A., Conley M.E., Cunningham-Rundles C., et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J. Allergy. Clin. Immunol. 2014;133:961-966.
Not in our library10.1016/j.jaci.2013.11.043
20.
Francica J.R., Sheng Z., Zhang Z., Nishimura Y., Shingai M., Ramesh A., Keele B.F., Schmidt S.D., Flynn B.J., Darko S., et al. Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nat. Commun. 2015;6:6565.
Not in our library10.1038/ncomms7565
21.
Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells · 2017
Corrected
22.
RNA-Based Vaccines in Cancer Immunotherapy · 2015
No notice
23.
Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N., Jayaraman M., Rajeev K.G., Cantley W.L., Dorkin J.R., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 2010;18:1357-1364.
Not in our library10.1038/mt.2010.85
24.
van den Elzen P., Garg S., Leon L., Brigl M., Leadbetter E.A., Gumperz J.E., Dascher C.C., Cheng T.Y., Sacks F.M., Illarionov P.A., et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature. 2005;437:906-910.
Not in our library10.1038/nature04001
25.
Kranz L.M., Diken M., Haas H., Kreiter S., Loquai C., Reuter K.C., Meng M., Fritz D., Vascotto F., Hefesha H., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396-401.
Not in our library10.1038/nature18300
26.
Lazzaro S., Giovani C., Mangiavacchi S., Magini D., Maione D., Baudner B., Geall A.J., De Gregorio E., D’Oro U., Buonsanti C. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology. 2015;146:312-326.
Not in our library10.1111/imm.12505
27.
Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells · 2019
No notice
28.
Brito L.A., Chan M., Shaw C.A., Hekele A., Carsillo T., Schaefer M., Archer J., Seubert A., Otten G.R., Beard C.W., et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 2014;22:2118-2129.
Not in our library10.1038/mt.2014.133
29.
Pardi N., Tuyishime S., Muramatsu H., Kariko K., Mui B.L., Tam Y.K., Madden T.D., Hope M.J., Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release. 2015;217:345-351.
Not in our library10.1016/j.jconrel.2015.08.007
30.
Bahl K., Senn J.J., Yuzhakov O., Bulychev A., Brito L.A., Hassett K.J., Laska M.E., Smith M., Almarsson O., Thompson J., et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol. Ther. 2017;25:1316-1327.
Not in our library10.1016/j.ymthe.2017.03.035
31.
Kowalczyk A., Doener F., Zanzinger K., Noth J., Baumhof P., Fotin-Mleczek M., Heidenreich R. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine. 2016;34:3882-3893.
Not in our library10.1016/j.vaccine.2016.05.046
32.
Oberli M.A., Reichmuth A.M., Dorkin J.R., Mitchell M.J., Fenton O.S., Jaklenec A., Anderson D.G., Langer R., Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017;17:1326-1335.
Not in our library10.1021/acs.nanolett.6b03329
33.
Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses · 2018
No notice
34.
Geall A.J., Verma A., Otten G.R., Shaw C.A., Hekele A., Banerjee K., Cu Y., Beard C.W., Brito L.A., Krucker T., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA. 2012;109:14604-14609.
Not in our library10.1073/pnas.1209367109
35.
Lindsay K.E., Bhosle S.M., Zurla C., Beyersdorf J., Rogers K.A., Vanover D., Xiao P., Arainga M., Shirreff L.M., Pitard B., et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat. Biomed. Eng. 2019;3:371-380.
Not in our library10.1038/s41551-019-0378-3
36.
Ols S., Lore K. Imaging the early fate of mRNA vaccines. Nat. Biomed. Eng. 2019;3:331-332.
Not in our library10.1038/s41551-019-0399-y
37.
Asselin-Paturel C., Brizard G., Chemin K., Boonstra A., O’Garra A., Vicari A., Trinchieri G. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med. 2005;201:1157-1167.
Not in our library10.1084/jem.20041930
38.
Simmons D.P., Wearsch P.A., Canaday D.H., Meyerson H.J., Liu Y.C., Wang Y., Boom W.H., Harding C.V. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 2012;188:3116-3126.
Not in our library10.4049/jimmunol.1101313
39.
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines · 2017
No notice
40.
Liang F., Lindgren G., Sandgren K.J., Thompson E.A., Francica J.R., Seubert A., De Gregorio E., Barnett S., O’Hagan D.T., Sullivan N.J., et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med. 2017;9.
Not in our library10.1126/scitranslmed.aal2094
41.
Bourquin C., Schmidt L., Hornung V., Wurzenberger C., Anz D., Sandholzer N., Schreiber S., Voelkl A., Hartmann G., Endres S. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood. 2007;109:2953-2960.
Not in our library10.1182/blood-2006-07-033258
42.
De Beuckelaer A., Pollard C., Van Lint S., Roose K., Van Hoecke L., Naessens T., Udhayakumar V.K., Smet M., Sanders N., Lienenklaus S., et al. Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. Mol. Ther. 2016;24:2012-2020.
Not in our library10.1038/mt.2016.161
43.
Pollard C., Rejman J., De Haes W., Verrier B., Van Gulck E., Naessens T., De Smedt S., Bogaert P., Grooten J., Vanham G., et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 2013;21:251-259.
Not in our library10.1038/mt.2012.202
44.
De Beuckelaer A., Grooten J., De Koker S. Type I Interferons Modulate CD8 (+) T Cell Immunity to mRNA Vaccines. Trends Mol. Med. 2017;23:216-226.
Not in our library10.1016/j.molmed.2017.01.006
45.
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection · 2020
No notice
46.
Bachmann M.F., Jennings G.T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010;10:787-796.
Not in our library10.1038/nri2868
47.
Mesin L., Ersching J., Victora G.D. Germinal Center B Cell Dynamics. Immunity. 2016;45:471-482.
Not in our library10.1016/j.immuni.2016.09.001
48.
Heesters B.A., van der Poel C.E., Das A., Carroll M.C. Antigen Presentation to B Cells. Trends Immunol. 2016;37:844-854.
Not in our library10.1016/j.it.2016.10.003
49.
Pardi N., Hogan M.J., Naradikian M.S., Parkhouse K., Cain D.W., Jones L., Moody M.A., Verkerke H.P., Myles A., Willis E., et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 2018;215:1571-1588.
Not in our library10.1084/jem.20171450
50.
Tam H.H., Melo M.B., Kang M., Pelet J.M., Ruda V.M., Foley M.H., Hu J.K., Kumari S., Crampton J., Baldeon A.D., et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc. Natl. Acad. Sci. USA. 2016;113:E6639-E6648.
Not in our library10.1073/pnas.1606050113
51.
An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs · 2016
No notice
52.
A thermostable messenger RNA based vaccine against rabies. · 2017
Not checked
53.
Alberer M., Gnad-Vogt U., Hong H.S., Mehr K.T., Backert L., Finak G., Gottardo R., Bica M.A., Garofano A., Koch S.D., et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390:1511-1520.
Not in our library10.1016/s0140-6736(17)31665-3
54.
Hekele A., Bertholet S., Archer J., Gibson D.G., Palladino G., Brito L.A., Otten G.R., Brazzoli M., Buccato S., Bonci A., et al. Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes. Infect. 2013;2:e52.
Not in our library10.1038/emi.2013.54
55.
Petsch B., Schnee M., Vogel A.B., Lange E., Hoffmann B., Voss D., Schlake T., Thess A., Kallen K.J., Stitz L., et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 2012;30:1210-1216.
Not in our library10.1038/nbt.2436
56.
Feldman R.A., Fuhr R., Smolenov I., Mick Ribeiro A., Panther L., Watson M., Senn J.J., Smith M., Almarsson Ö., Pujar H.S., et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37:3326-3334.
Not in our library10.1016/j.vaccine.2019.04.074
57.
Richner J.M., Himansu S., Dowd K.A., Butler S.L., Salazar V., Fox J.M., Julander J.G., Tang W.W., Shresta S., Pierson T.C., et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell. 2017;169:176.
Not in our library10.1016/j.cell.2017.03.016
58.
Pardi N., Hogan M.J., Pelc R.S., Muramatsu H., Andersen H., DeMaso C.R., Dowd K.A., Sutherland L.L., Scearce R.M., Parks R., et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543:248-251.
Not in our library10.1038/nature21428
59.
Richner J.M., Jagger B.W., Shan C., Fontes C.R., Dowd K.A., Cao B., Himansu S., Caine E.A., Nunes B.T.D., Medeiros D.B.A., et al. Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. Cell. 2017;170:273-283.e12.
Not in our library10.1016/j.cell.2017.06.040
60.
Erasmus J.H., Khandhar A.P., Guderian J., Granger B., Archer J., Archer M., Gage E., Fuerte-Stone J., Larson E., Lin S., et al. A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika. Mol. Ther. 2018;26:2507-2522.
Not in our library10.1016/j.ymthe.2018.07.010
61.
John S., Yuzhakov O., Woods A., Deterling J., Hassett K., Shaw C.A., Ciaramella G. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018;36:1689-1699.
Not in our library10.1016/j.vaccine.2018.01.029
62.
Van Craenenbroeck A.H., Smits E.L., Anguille S., Van de Velde A., Stein B., Braeckman T., Van Camp K., Nijs G., Ieven M., Goossens H., et al. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells. Transplantation. 2015;99:120-127.
Not in our library10.1097/tp.0000000000000272
63.
Van Gulck E., Vlieghe E., Vekemans M., Van Tendeloo V.F., Van De Velde A., Smits E., Anguille S., Cools N., Goossens H., Mertens L., et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. Aids. 2012;26:F1-F12.
Not in our library10.1097/qad.0b013e32834f33e8
64.
Routy J.P., Boulassel M.R., Yassine-Diab B., Nicolette C., Healey D., Jain R., Landry C., Yegorov O., Tcherepanova I., Monesmith T., et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 2010;134:140-147.
Not in our library10.1016/j.clim.2009.09.009
65.
Allard S.D., De Keersmaecker B., de Goede A.L., Verschuren E.J., Koetsveld J., Reedijk M.L., Wylock C., De Bel A.V., Vandeloo J., Pistoor F., et al. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin. Immunol. 2012;142:252-268.
Not in our library10.1016/j.clim.2011.10.010
66.
Gandhi R.T., Kwon D.S., Macklin E.A., Shopis J.R., McLean A.P., McBrine N., Flynn T., Peter L., Sbrolla A., Kaufmann D.E., et al. Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J. Acquir. Immune. Defic. Syndr. 2016;71:246-253.
Not in our library10.1097/qai.0000000000000852
67.
Meyer M., Huang E., Yuzhakov O., Ramanathan P., Ciaramella G., Bukreyev A. Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease. J. Infect. Dis. 2018;217:451-455.
Not in our library10.1093/infdis/jix592
68.
Mulligan M.J., Lyke K.E., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Raabe V., Bailey R., Swanson K.A., et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589-593.
Not in our library10.1038/s41586-020-2639-4
69.
Walsh E.E., Frenck R.W., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439-2450.
Not in our library10.1056/nejmoa2027906
70.
Corbett K.S., Edwards D., Leist S.R., Abiona O.M., Boyoglu-Barnum S., Gillespie R.A., Himansu S., Schafer A., Ziwawo C.T., DiPiazza A.T., et al. SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. Nature. 2020;586:567-571.
Not in our library10.1038/s41586-020-2622-0
71.
Corbett K.S., Flynn B., Foulds K.E., Francica J.R., Boyoglu-Barnum S., Werner A.P., Flach B., O’Connell S., Bock K.W., Minai M., et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 2020;383:1544-1555.
Not in our library10.1056/nejmoa2024671
72.
Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., et al. An mRNA Vaccine against SARS-CoV-2-Preliminary Report. N. Engl. J. Med. 2020;383:1920-1931.
Not in our library10.1056/nejmoa2022483
73.
Anderson E.J., Rouphael N.G., Widge A.T., Jackson L.A., Roberts P.C., Makhene M., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N. Engl. J. Med. 2020;383:2427-2438.
Not in our library10.1056/nejmoa2028436
74.
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents · 2021
No notice
75.
Rauch S., Gooch K., Hall Y., Salguero F.J., Dennis M.J., Gleeson F.V., Harris D., Ho C., Humphries H.E., Longet S., et al. mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. bioRxiv. 2020.
Not in our library10.1101/2020.12.23.424138
76.
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 · 2021
No notice
77.
Weissman D., Alameh M.G., de Silva T., Collini P., Hornsby H., Brown R., LaBranche C.C., Edwards R.J., Sutherland L., Santra S., et al. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host Microbe. 2020;29:23-31.e4.
Not in our library10.1016/j.chom.2020.11.012
78.
Xie X., Zou J., Fontes-Garfias C.R., Xia H., Swanson K.A., Cutler M., Cooper D., Menachery V.D., Weaver S., Dormitzer P.R., et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv. 2021.
Not in our library10.1101/2021.01.07.425740
79.
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 · 2020
No notice
80.
Lipsitch M., Grad Y.H., Sette A., Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat. Rev. Immunol. 2020;20:709-713.
Not in our library10.1038/s41577-020-00460-4
81.
Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L.M., Vormehr M., Baum A., Pascal K., Quandt J., Maurus D., et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594-599.
Not in our library10.1038/s41586-020-2814-7
82.
Laczko D., Hogan M.J., Toulmin S.A., Hicks P., Lederer K., Gaudette B.T., Castano D., Amanat F., Muramatsu H., Oguin T.H., et al. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity. 2020;53:724-732.e7.
Not in our library10.1016/j.immuni.2020.07.019
83.
Zhang N.N., Li X.F., Deng Y.Q., Zhao H., Huang Y.J., Yang G., Huang W.J., Gao P., Zhou C., Zhang R.R., et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020;182:1271-1283.e16.
Not in our library10.1016/j.cell.2020.07.024
84.
Kose N., Fox J.M., Sapparapu G., Bombardi R., Tennekoon R.N., de Silva A.D., Elbashir S.M., Theisen M.A., Humphris-Narayanan E., Ciaramella G., et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol. 2019;4.
Not in our library10.1126/sciimmunol.aaw6647

Cited by papers we hold 4

Advances in COVID-19 mRNA vaccine development · 2022
No notice
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond · 2021
No notice
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics · 2021
No notice
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.